Guardant Health Inc.
Graf
Godt at vide: Investering i aktier giver typisk et positivt afkast på lang sigt, men indebærer også risiko. Du kan miste dele af eller hele din investering. Tidligere data for denne aktie er ikke en pålidelig indikator for fremtidige afkast. Data fra eksterne udbydere er ikke blevet ændret af Saxo Bank. Se fuld ansvarsfraskrivelse for data.
Om Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
/ 